Literature DB >> 10425523

Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I.

S Bramani1, H Song, J Beattie, E Tonner, D J Flint, G J Allan.   

Abstract

The highly conserved N-and C-terminal domains of IGFBPs are believed to participate in IGF binding, but only recently have some of the critical residues in the IGFBP sequence involved in ligand binding been identified. Here we describe two highly conserved amino acids in the C-terminal domain of rat IGFBP-5 that are involved in binding IGF-I. Site-directed mutagenesis was used to produce two mutants, G203K and Q209A, of rIGFBP-5. Relative to wild-type rIGFBP-5, an 8-fold reduction in affinity for human IGF-I was found for recombinant G203K protein in both IGF-I ligand blots and solution phase ligand binding assays, and a 7-and 6-fold reduction for Q209A respectively. This shows that Gly203 and Gln209 in IGFBP-5 are important determinants in binding IGF-I, and due to their complete conservation in all IGFBP sequences, we suggest that they are likely to be involved in binding IGF-I in all six binding proteins. In addition, these two non-basic residues lie within the ECM binding region (201-218) of IGFBP-5, demonstrating that the C-terminus contains partially overlapping IGF-I and ECM binding sites. We therefore propose that heparin binding to basic amino acids in IGFBP-5 between 201-218 may physically occlude subsequent interaction between IGF-I and Gly203/Gln209, and that this may explain previous work of others showing reduced affinity of ECM bound IGFBP-5 for IGF-I.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425523     DOI: 10.1677/jme.0.0230117

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  6 in total

Review 1.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

2.  Upregulated Ribosomal Pathway Impairs Follicle Development in a Polycystic Ovary Syndrome Mouse Model: Differential Gene Expression Analysis of Oocytes.

Authors:  Natsuki Nakanishi; Satoko Osuka; Tomohiro Kono; Hisato Kobayashi; Shinya Ikeda; Bayasula Bayasula; Reina Sonehara; Mayuko Murakami; Sayako Yoshita; Natsuki Miyake; Ayako Muraoka; Yukiyo Kasahara; Tomohiko Murase; Tomoko Nakamura; Maki Goto; Akira Iwase; Hiroaki Kajiyama
Journal:  Reprod Sci       Date:  2022-10-04       Impact factor: 2.924

Review 3.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

4.  Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.

Authors:  Yousef Hawsawi; Matthew P Humphries; Alexander Wright; Angelene Berwick; Mike Shires; Hanaa Al-Kharobi; Reem El-Gendy; Maria Jove; Chris Twelves; Valerie Speirs; James Beattie
Journal:  Oncotarget       Date:  2016-05-31

Review 5.  Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer.

Authors:  Mustafa Akkiprik; Yumei Feng; Huamin Wang; Kexin Chen; Limei Hu; Aysegul Sahin; Savitri Krishnamurthy; Ayse Ozer; Xishan Hao; Wei Zhang
Journal:  Breast Cancer Res       Date:  2008-08-11       Impact factor: 6.466

Review 6.  Insulin-Like Growth Factor Binding Protein-5 in Physiology and Disease.

Authors:  Cumming Duan; John B Allard
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-03       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.